136 related articles for article (PubMed ID: 28713889)
1. TFE3 regulates renal adenocarcinoma cell proliferation via activation of the mTOR pathway.
Fang Y; Bao W; Rao Q; Wang X; Xia Q; Shen Q; Zhou X; Yao B
Mol Med Rep; 2017 Sep; 16(3):2721-2725. PubMed ID: 28713889
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.
Damayanti NP; Budka JA; Khella HWZ; Ferris MW; Ku SY; Kauffman E; Wood AC; Ahmed K; Chintala VN; Adelaiye-Ogala R; Elbanna M; Orillion A; Chintala S; Kao C; Linehan WM; Yousef GM; Hollenhorst PC; Pili R
Clin Cancer Res; 2018 Dec; 24(23):5977-5989. PubMed ID: 30061365
[TBL] [Abstract][Full Text] [Related]
3. Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion.
Kauffman EC; Lang M; Rais-Bahrami S; Gupta GN; Wei D; Yang Y; Sourbier C; Srinivasan R
BMC Cancer; 2019 Sep; 19(1):917. PubMed ID: 31519159
[TBL] [Abstract][Full Text] [Related]
4. mTOR Inhibition Increases Transcription Factor E3 (TFE3) Activity and Modulates Programmed Death-Ligand 1 (PD-L1) Expression in Translocation Renal Cell Carcinoma.
Lee HJ; Shin DH; Song JS; Park JY; Kim SY; Hwang CS; Na JY; Lee JH; Kim JY; Park SW; Sol MY
Am J Pathol; 2021 Nov; 191(11):1999-2008. PubMed ID: 34358517
[TBL] [Abstract][Full Text] [Related]
5. HOXA6 inhibits cell proliferation and induces apoptosis by suppressing the PI3K/Akt signaling pathway in clear cell renal cell carcinoma.
Wu F; Wu S; Tong H; He W; Gou X
Int J Oncol; 2019 Jun; 54(6):2095-2105. PubMed ID: 31081053
[TBL] [Abstract][Full Text] [Related]
6. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
7. TFE3 fusions escape from controlling of mTOR signaling pathway and accumulate in the nucleus promoting genes expression in Xp11.2 translocation renal cell carcinomas.
Yin X; Wang B; Gan W; Zhuang W; Xiang Z; Han X; Li D
J Exp Clin Cancer Res; 2019 Mar; 38(1):119. PubMed ID: 30849994
[TBL] [Abstract][Full Text] [Related]
8. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.
Reis H; Hager T; Wohlschlaeger J; Bauer S; Katenkamp K; Katenkamp D; Baba HA
Hum Pathol; 2013 Oct; 44(10):2266-74. PubMed ID: 23871289
[TBL] [Abstract][Full Text] [Related]
9. The renal cell carcinoma-associated oncogenic fusion protein PRCCTFE3 provokes p21 WAF1/CIP1-mediated cell cycle delay.
Medendorp K; van Groningen JJ; Vreede L; Hetterschijt L; Brugmans L; van den Hurk WH; van Kessel AG
Exp Cell Res; 2009 Aug; 315(14):2399-409. PubMed ID: 19422821
[TBL] [Abstract][Full Text] [Related]
10. TFE3-SLC36A1 axis promotes resistance to glucose starvation in kidney cancer cells.
Lv S; Zhang Z; Li Z; Ke Q; Ma X; Li N; Zhao X; Zou Q; Sun L; Song T
J Biol Chem; 2024 May; 300(5):107270. PubMed ID: 38599381
[TBL] [Abstract][Full Text] [Related]
11. The tumor suppressor FLCN mediates an alternate mTOR pathway to regulate browning of adipose tissue.
Wada S; Neinast M; Jang C; Ibrahim YH; Lee G; Babu A; Li J; Hoshino A; Rowe GC; Rhee J; Martina JA; Puertollano R; Blenis J; Morley M; Baur JA; Seale P; Arany Z
Genes Dev; 2016 Nov; 30(22):2551-2564. PubMed ID: 27913603
[TBL] [Abstract][Full Text] [Related]
12. miR‑205 suppresses cell proliferation, invasion, and metastasis via regulation of the PTEN/AKT pathway in renal cell carcinoma.
Wang H; Chen B; Duan B; Zheng J; Wu X
Mol Med Rep; 2016 Oct; 14(4):3343-9. PubMed ID: 27498834
[TBL] [Abstract][Full Text] [Related]
13. TFE3-positive renal cell carcinomas are not always Xp11 translocation carcinomas: Report of a case with a TPM3-ALK translocation.
Thorner PS; Shago M; Marrano P; Shaikh F; Somers GR
Pathol Res Pract; 2016 Oct; 212(10):937-942. PubMed ID: 27450657
[TBL] [Abstract][Full Text] [Related]
14. Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma.
Chen F; Zhang Y; Şenbabaoğlu Y; Ciriello G; Yang L; Reznik E; Shuch B; Micevic G; De Velasco G; Shinbrot E; Noble MS; Lu Y; Covington KR; Xi L; Drummond JA; Muzny D; Kang H; Lee J; Tamboli P; Reuter V; Shelley CS; Kaipparettu BA; Bottaro DP; Godwin AK; Gibbs RA; Getz G; Kucherlapati R; Park PJ; Sander C; Henske EP; Zhou JH; Kwiatkowski DJ; Ho TH; Choueiri TK; Hsieh JJ; Akbani R; Mills GB; Hakimi AA; Wheeler DA; Creighton CJ
Cell Rep; 2016 Mar; 14(10):2476-89. PubMed ID: 26947078
[TBL] [Abstract][Full Text] [Related]
15. Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis.
Klatte T; Streubel B; Wrba F; Remzi M; Krammer B; de Martino M; Waldert M; Marberger M; Susani M; Haitel A
Am J Clin Pathol; 2012 May; 137(5):761-8. PubMed ID: 22523215
[TBL] [Abstract][Full Text] [Related]
16. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
[TBL] [Abstract][Full Text] [Related]
17. G Protein Alpha S Subunit Promotes Cell Proliferation of Renal Cell Carcinoma with Involvement of Protein Kinase A Signaling.
Zhang B; Sun N; Mu X; Zhi L; Zhai L; Jiang Y; Fu Z; Yao Z
DNA Cell Biol; 2017 Mar; 36(3):237-242. PubMed ID: 28051330
[TBL] [Abstract][Full Text] [Related]
18. TFE3-PD-L1 axis is pivotal for sunitinib resistance in clear cell renal cell carcinoma.
Guo X; Li R; Bai Q; Jiang S; Wang H
J Cell Mol Med; 2020 Dec; 24(24):14441-14452. PubMed ID: 33145941
[TBL] [Abstract][Full Text] [Related]
19. [Overexpression of SEPP1 inhibits the proliferation and induces cell cycle G2/M arrest of 786-O and 769-P human renal carcinoma cells].
Liu K; Zhao C; Chen J; Wu S; Yao Y; Wu C; Luo G; Zhang X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Jun; 32(6):764-9. PubMed ID: 27371843
[TBL] [Abstract][Full Text] [Related]
20. Altered transcription factor E3 expression in unclassified adult renal cell carcinoma indicates adverse pathological features and poor outcome.
Mir MC; Trilla E; de Torres IM; Panizo A; Zlotta AR; Van Rhijn B; Morote J
BJU Int; 2011 Jul; 108(2 Pt 2):E71-6. PubMed ID: 21070573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
